MINIREVIEWS

4734 Inflammatory myofibroblastic tumor of the distal common bile duct: Literature review with focus on pathological examination
Cordier F, Hooorens A, Ferdinande L, Van Dorpe J, Creytens D

4740 Probiotics and autoprobiotics for treatment of Helicobacter pylori infection
Baryshnikova NV, Ilina AS, Ermolenko EI, Uspenskiy YP, Suvorov AN

4752 Plant-based diet and its effect on coronary artery disease: A narrative review

ORIGINAL ARTICLE

Clinical and Translational Research

4763 Identification of survival-associated biomarkers based on three datasets by bioinformatics analysis in gastric cancer

4788 High expression of autophagy-related gene EIF4EBP1 could promote tamoxifen resistance and predict poor prognosis in breast cancer

4800 Delineation of fatty acid metabolism in gastric cancer: Therapeutic implications

4814 Mechanical analysis of the femoral neck dynamic intersection system with different nail angles and clinical applications
Wang Y, Ma JX, Bai HH, Lu B, Sun L, Jin HZ, Ma XL

Retrospective Cohort Study

4824 Development and validation of a predictive model for spinal fracture risk in osteoporosis patients
Lin XM, Shi ZC

Retrospective Study

4833 Risk prediction model for distinguishing Gram-positive from Gram-negative bacteremia based on age and cytokine levels: A retrospective study
Zhang W, Chen T, Chen HJ, Chen N, Xing ZX, Fu XY

4843 Sudden death in the southern region of Saudi Arabia: A retrospective study
Al-Enam AMA, Dajam A, Alrajhi M, Alfaifi W, Al-Shraim M, Helaly AM
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>4852</td>
<td>Diagnostic value of preoperative examination for evaluating margin status in breast cancer</td>
<td>Liu P, Zhao Y, Rong DD, Li KF, Wang YJ, Zhao J, Kang H</td>
</tr>
<tr>
<td>4865</td>
<td>Defining the awareness and attitude of the clinicians through pharmacovigilance in Turkey</td>
<td>Aydin OC, Aydin S, Guney HZ</td>
</tr>
<tr>
<td>4874</td>
<td>Predictive value of the trans-perineal three-dimensional ultrasound measurement of the pubic arch angle for vaginal delivery</td>
<td>Liang ZW, Gao WL</td>
</tr>
<tr>
<td>4883</td>
<td>Microwave ablation of solitary T1N0M0 papillary thyroid carcinoma: A case report</td>
<td>Dionísio T, Lajut L, Sousa F, Violante L, Sousa P</td>
</tr>
<tr>
<td>4890</td>
<td>Acute spinal subdural haematoma complicating a posterior spinal instrumented fusion for congenital scoliosis: A case report</td>
<td>Michon du Marais G, Tabard-Fougère A, Dayer R</td>
</tr>
<tr>
<td>4903</td>
<td><em>ABCB4</em> gene mutation-associated cirrhosis with systemic amyloidosis: A case report</td>
<td>Cheng N, Qin YJ, Zhang Q, Li H</td>
</tr>
<tr>
<td>4912</td>
<td>Metagenomic next-generation sequencing in the diagnosis of neurocysticercosis: A case report</td>
<td>Xu WB, Fu JJ, Yuan XJ, Xian QJ, Zhang LJ, Song PP, You ZQ, Wang CT, Zhao QG, Pang F</td>
</tr>
<tr>
<td>4920</td>
<td>Drug-coated balloons for treating <em>de novo</em> lesions in large coronary vessels: A case report</td>
<td>Zhang QZ, Qin YR, Yin M, Chen XH, Chen L, Liang WY, Wei XQ</td>
</tr>
<tr>
<td>4926</td>
<td>Pretreatment with a modified St. Thomas’ solution in patients with severe upper limb injuries: Four case reports</td>
<td>Sun ZY, Li LY, Xing JX, Tong LC, Li Y</td>
</tr>
<tr>
<td>4932</td>
<td>Unexpected diffuse lung lesions in a patient with pulmonary alveolar proteinosis: A case report</td>
<td>Jian L, Zhao QQ</td>
</tr>
<tr>
<td>4937</td>
<td>Contrast-induced ischemic colitis following coronary angiography: A case report</td>
<td>Qiu H, Li WP</td>
</tr>
<tr>
<td>4944</td>
<td>Posterior pedicle screw fixation combined with local steroid injections for treating axial eosinophilic granulomas and atlantoaxial dislocation: A case report</td>
<td>Tu CQ, Chen ZD, Yao XT, Jiang YJ, Zhang BF, Lin B</td>
</tr>
</tbody>
</table>
Laryngospasm as an uncommon presentation in a patient with anti-N-methyl-D-aspartate receptor encephalitis: A case report

Wang L, Su HJ, Song GJ
ABOUT COVER
Editorial Board Member of *World Journal of Clinical Cases*, Kengo Moriyama, MD, PhD, Associate Professor, Department of Clinical Health Science, Tokai University School of Medicine, Tokai University Hachioji Hospital, Hachioji 1838, Tokyo, Japan. osaru3moving@gmail.com

AIMS AND SCOPE
The primary aim of *World Journal of Clinical Cases* (WJCC, *World J Clin Cases*) is to provide scholars and readers from various fields of clinical medicine with a platform to publish high-quality clinical research articles and communicate their research findings online.

WJCC mainly publishes articles reporting research results and findings obtained in the field of clinical medicine and covering a wide range of topics, including case control studies, retrospective cohort studies, retrospective studies, clinical trials studies, observational studies, prospective studies, randomized controlled trials, randomized clinical trials, systematic reviews, meta-analysis, and case reports.

INDEXING/ABSTRACTING
The WJCC is now abstracted and indexed in Science Citation Index Expanded (SCIE, also known as SciSearch®), Journal Citation Reports/Science Edition, Current Contents®/Clinical Medicine, PubMed, PubMed Central, Reference Citation Analysis, China National Knowledge Infrastructure, China Science and Technology Journal Database, and Superstar Journals Database. The 2023 Edition of Journal Citation Reports® cites the 2022 impact factor (IF) for WJCC as 1.1; IF without journal self cites: 1.1; 5-year IF: 1.3; Journal Citation Indicator: 0.26; Ranking: 133 among 167 journals in medicine, general and internal; and Quartile category: Q4.

RESPONSIBLE EDITORS FOR THIS ISSUE
Production Editor: Hua-Ge Yu; Production Department Director: Xu Guo; Editorial Office Director: Jin-Lei Wang.

NAME OF JOURNAL
World Journal of Clinical Cases

ISSN
ISSN 2307-8960 (online)

LAUNCH DATE
April 16, 2013

FREQUENCY
Thrice Monthly

EDITORS-IN-CHIEF
Bao-Gan Peng, Jerzy Tadeusz Chudek, George Kontogeorgos, Maurizio Serati, Ja Hyeon Ku

EDITORIAL BOARD MEMBERS
https://www.wjgnet.com/2307-8960/editorialboard.htm

PUBLICATION DATE
July 16, 2023

COPYRIGHT
© 2023 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS
https://www.wjgnet.com/bpg/gerinfo/204

GUIDELINES FOR ETHICS DOCUMENTS
https://www.wjgnet.com/bpg/gerinfo/287

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH
https://www.wjgnet.com/bpg/gerinfo/240

PUBLICATION ETHICS
https://www.wjgnet.com/bpg/gerinfo/288

PUBLICATION MISCONDUCT
https://www.wjgnet.com/bpg/gerinfo/208

ARTICLE PROCESSING CHARGE
https://www.wjgnet.com/bpg/gerinfo/242

STEPS FOR SUBMITTING MANUSCRIPTS
https://www.wjgnet.com/bpg/gerinfo/239

ONLINE SUBMISSION
https://www.f6publishing.com
Delineation of fatty acid metabolism in gastric cancer: Therapeutic implications

Yu Fu, Bin Wang, Peng Fu, Lei Zhang, Yi Bao, Zhen-Zhen Gao

BACKGROUND
The prognosis of gastric cancer is extremely poor. Metabolic reprogramming involving lipids has been associated with cancer occurrence and progression.

AIM
To illustrate fatty acid metabolic mechanisms in gastric cancer, detect core genes, develop a prognostic model, and provide treatment options.

METHODS
Raw data from The Cancer Genome Atlas and Gene Expression Omnibus databases were collected and analyzed. Differentially expressed fatty acid metabolism genes were identified and incorporated into a risk model based on least absolute shrinkage and selection operator regression analysis. Then, patients from The Cancer Genome Atlas were assigned to high- and low-risk cohorts according to the mean value of the risk score as the threshold, which was verified in the Gene Expression Omnibus database. Relationships between chemotherapeutic sensitivity and tumor microenvironment features were assessed.

RESULTS
An integrated evaluation was performed in this study. Fatty acid metabolism-related genes were used to construct the risk model. Patients classified into the high-risk cohort were considered to be resistant to chemotherapy based on results of the “pRRophetic” R package. Patients in the high-risk cohort were associated with type I/II interferon activation, increased inflammation level, immune cell...
infiltration, and tumor immune dysfunction based on the exclusion algorithm, indicating the potential benefit of immunotherapy in these patients.

CONCLUSION
We constructed a fatty acid-related risk score model to assess the comprehensive fatty acid features in gastric cancer and validated its vital role in prognosis, chemotherapy sensitivity, and immunotherapy.

Key Words: Stomach neoplasms; Fatty acids; Metabolism; Risk assessment; Immunotherapy

©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: We established a prognostic risk model using data collected from The Cancer Genome Atlas database, explored the function of the risk model, and identified the relationship between the risk model and clinical features. The findings of our study provide innovative therapeutic options in clinical practice.

INTRODUCTION
Gastric cancer (GC) is associated with poor overall survival and is one of the most common types of fatal cancer worldwide[1,2]. Regional differences in the incidence of GC have been reported. Globally, the 5-year overall survival rate is reported to be less than 25%, given the late-stage presentation, metastasis, tumor heterogeneity, and the intrinsic therapeutic resistance of GC[3]. Joshi et al[3] investigated GC biology and found that, compared with cases in Western countries, GC cases in eastern Asia were characterized by lower proportions of signet ring cell histology. However, the 5-year overall survival rates remain low. Identifying the novel mechanisms underlying GC is of critical importance to develop treatment strategies that can be used in clinical practice. In general, cancer is characterized by the interactions between solitary metabolic features and the surrounding complex tumor environment[4]. Carbohydrates, lipids, and amino acids are the main nutrients in cancer cells, among which lipids are crucial mediators in energy metabolism and signal transduction. Importantly, fatty acids are the basic components of diverse types of lipids[5,6]. Furthermore, metabolic reprogramming has been identified as a critical hallmark of tumor cell proliferation and differentiation. Ma et al[7] described various transcription factors controlling gene expression programs including fatty acid metabolism (FAM)-related genes. Khan et al[8] confirmed that SIRT6 could regulate fatty acid transport by suppressing PPAR signaling, thereby promoting tumor progression. Luo et al[9] demonstrated that the critical role of fatty acid oxidation in CD8+ T cell memory formation, which is crucial in the tumor microenvironment. Garcia et al[10] found that elevated levels of fatty acid may accelerate cancer progression through endoplasmic reticulum stress by modulating the forkhead box (FOX)O3-FOXO1 axis. In addition, Zhang et al[11] demonstrated that fatty acid-induced CD36 expression promoted the progression of GC by activating the nuclear factor-kB pathway and direct binding of CD36 at S468 and T470. Adenosine triphosphate citrate lyase, acetyl-CoA synthases, acetyl-CoA carboxylase, and fatty acid synthase are crucial enzymes in fatty acid synthesis[12]. Although various molecules have been identified in GC metastasis, uncovering novel links between fatty acids and the tumor environment are necessary for a comprehensive understanding of GC and will contribute to accurate diagnosis, prognosis prediction, and recurrence risk and metastasis assessments in patients with GC. In this study, we constructed a novel prognostic risk model for GC based on FAM-related genes. We examined the mechanisms underlying FAM in GC, the relationship between the risk of GC and tumor microenvironment characteristics, and treatment strategies for GC.

MATERIALS AND METHODS
Data download and analysis
Raw data for GC were downloaded from The Cancer Genome Atlas (TCGA) project (https://portal.gdc.cancer.gov/) and the Gene Expression Omnibus (GEO) database (https://www.ncbi.nlm.nih.gov/geo/). Transcription profiling data from TCGA-stomach adenocarcinoma project were collected in the stomach carcinoma-counts workflow type. Simple nucleotide variation data were also retrieved as masked somatic mutation data from TCGA-GDC portal. Clinical information of patients with GC including age, sex, tumor stage, tumor grade, T/N/M (tumor, node, metastasis) stages, and survival information was also obtained. The microarray data from the GSE84437 dataset in the GEO GPL6947 platform were also acquired. The annotation platform was implemented to convert the Entrez Gene identifiers (IDs) of
Detection of differentially expressed genes and functional enrichment analysis between normal and cancer samples

Generally, FAM-related genes were acquired, as previously described. Differentially expressed genes (DEGs) in normal and tumor cases were identified using the “limma” statistical package in R (version 4.1.3; R Foundation for Statistical Computing, Vienna, Austria). A false discovery rate (FDR) < 0.05 was considered the cutoff value. Conversion from Entrez Gene IDs to gene symbols was processed using the “org.Hs.eg.db” R package. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis were conducted to detect the biological characteristics using the “clusterProfiler” R package. Finally, enrichment analysis results were visualized using the “enrich plot” and “ggplot2” packages. A P value less than 0.05 (P < 0.05) was considered statistically significant.

Establishment and validation of prognostic risk model

Clinical samples from TCGA database were defined as the training cohort, and the GSE84437 dataset from the GEO database was defined as the validation cohort. We combined the expression level of FAM-related genes with clinical information using the patient IDs. Genes related to survival were based on DEGs and analyzed using univariable cox regression, in line with the validation cohort. Then, genes with statistically significant values (< 0.05) were selected for further analysis. Prognostic genes were generated through least absolute shrinkage and selection operator (LASSO) cox regression analysis using the “glmnet” package, and a prognostic model was constructed. The risk score was calculated as described previously. All samples were segmented into high-risk and low-risk cohorts based on the median value of the risk scores. Kaplan–Meier analysis and the log-rank test were applied to determine the survival difference between low- and high-risk score groups. Finally, the “survivalROC” package was used to assess the predictive accuracy of the prognostic risk model. All data were verified in the validation group.

Principal component analysis and gene set variation analysis

The Ggplot2 and limma R packages were utilized to conduct principal component analysis (PCA) of gene expression profiles to construct a risk model from TCGA database. Accordingly, PCA was performed on FAM-related gene expression. Two-dimensional diagrams were then visualized to present the results. In addition, gene set variation analysis (GSVA), a non-parametric method implementing gene sets from the molecular signature (https://www.gsea-msigdb.org/gsea/msigdb) database was applied to identify the biological function and pathways between high- and low-risk groups. An FDR < 0.05 was considered statistically significant.

Construction of protein-protein interaction network

The expression profiles of DEGs between high- and low-risk models were analyzed. The gene symbols were merged into an online STRING database (https://cn.string-db.org/) to establish the protein-protein interaction (PPI) network with interaction scores > 0.7. The PPI network was then presented using Cytoscape software (version: 3.9.2, The Cytoscape Consortium, San Diego, CA, United States). Next, CytoHubba (version 0.1) was applied to generate hub genes from all the DEGs. Based on the previous genes, GO and KEGG enrichment analyses were used to illustrate the biological functions of the identified hub genes. Finally, the differences in the degree of immune cell infiltration based on the expression of hub genes were determined.

Statistical analysis

R packages including “pRRophetic” and “rms” were applied to demonstrate the predictive value of the clinical features. The Wilcoxon rank sum and Kruskall–Wallis tests were used to perform group comparisons. Kaplan–Meier analysis was used to assess survival. Univariable and multivariable regression models were applied to identify independent factors related to overall survival in GC. Receiver operating characteristic (ROC) curves were drawn to verify the value of the risk model. All analyses were performed using R (version 4.1.3). Statistical significance was defined as P < 0.05.

RESULTS

Functional analysis of FAM-related genes between normal and cancer samples from TCGA database

We conducted differential expression analysis of FAM-related genes using the limma R package. In total, 113 DEGs with \(|\log FC| > 1.5\) and FDR ≤ 0.05 were identified in TCGA cohort, of which, 60 genes were upregulated, and 53 genes were downregulated, as shown in Supplementary Figure 1A. Thereafter, functional analysis was conducted for the DEGs. FAM-related genes were enriched in fatty acid metabolic, acyl-CoA metabolic, and fatty acid biosynthetic processes in GO as well as KEGG analyses (Supplementary Figure 1B–C).

Construction and validation of the prognostic risk model in GC

Clinical cases from TCGA database cohort were included in the training set. Univariable cox regression analysis was conducted among the 113 DEGs related to FAM. Overall, statistically significant links to GC prognosis were detected in 17 genes (P < 0.05; Figure 1A). Next, the relationship among the 17 FAM-related genes was calculated using a correlation test (Figure 1B). In total, FAM-related gene mutations occurred in 65 patients, equating to a frequency of 16.5% (Figure 1C). The cyclooxygenase 1 (PTGS1) gene had the highest mutation frequency among patients with GC. Furthermore, a co-occurrence mutation was demonstrated between PTGS1 and other FAM-related genes. LASSO
### Table A

<table>
<thead>
<tr>
<th>Gene</th>
<th>P value</th>
<th>Hazard ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>MAOA</td>
<td>0.031</td>
<td>1.160(1.014-1.327)</td>
</tr>
<tr>
<td>CD36</td>
<td>0.002</td>
<td>1.336(1.115-1.601)</td>
</tr>
<tr>
<td>ELOVL2</td>
<td>0.007</td>
<td>1.487(1.115-1.984)</td>
</tr>
<tr>
<td>ACBD5</td>
<td>0.042</td>
<td>0.693(0.487-0.987)</td>
</tr>
<tr>
<td>ABCD1</td>
<td>0.047</td>
<td>0.860(0.643-0.997)</td>
</tr>
<tr>
<td>GLUL</td>
<td>0.049</td>
<td>1.372(1.002-1.878)</td>
</tr>
<tr>
<td>ADH4</td>
<td>0.037</td>
<td>1.124(1.007-1.256)</td>
</tr>
<tr>
<td>GGT5</td>
<td>0.007</td>
<td>1.365(1.090-1.710)</td>
</tr>
<tr>
<td>PTGS1</td>
<td>0.025</td>
<td>1.282(1.032-1.592)</td>
</tr>
<tr>
<td>ELOV4</td>
<td>&lt;0.001</td>
<td>1.486(1.174-1.830)</td>
</tr>
<tr>
<td>GABARAPL1</td>
<td>0.028</td>
<td>1.298(1.029-1.638)</td>
</tr>
<tr>
<td>FMO1</td>
<td>0.043</td>
<td>1.265(1.008-1.587)</td>
</tr>
<tr>
<td>DHGDH</td>
<td>0.037</td>
<td>0.746(0.567-0.983)</td>
</tr>
<tr>
<td>PTGIS</td>
<td>0.033</td>
<td>1.141(1.010-1.289)</td>
</tr>
<tr>
<td>CPT1C</td>
<td>0.035</td>
<td>1.269(1.017-1.585)</td>
</tr>
<tr>
<td>ADH1B</td>
<td>0.043</td>
<td>1.157(1.004-1.332)</td>
</tr>
<tr>
<td>ACOX2</td>
<td>0.043</td>
<td>1.198(1.006-1.428)</td>
</tr>
</tbody>
</table>

### Diagram B

- **X-axis**: log(2) P value
- **Y-axis**: log(2) Hazard ratio
- **Legend**:
  - P < 0.01
  - P < 0.05
  - > 3 (Co-occurrence)
  - 2
  - 1
  - 1
  - > 3 (Mutually exclusive)

### Diagram C

- **Title**: Altered in 65 (16.5%) of 394 samples
- **Genes**: PTGS1, ABCD1, CPT1C, GABARAPL1, FMO1, PTGIS, MAOA, CD36, ACBD5, GLUL, ELOVL2, ELOVL4, GGT5, ADH1B, ADH4, DHGDH
- **Color Coding**:
  - Missense mutation
  - Splice site
  - Frame shift deleterious
  - Nonsense mutation
  - Frameshift insertion
  - Translation start site
  - Multi-Hit

### Diagram D

- **Title**: Partial likelihood deviance
- **X-axis**: log(λ)
- **Y-axis**: Partial likelihood deviance

### Diagram E

- **Title**: Coefficients
- **X-axis**: log(λ)
- **Y-axis**: Coefficients
- **Legend**:
  - 0.3
  - 0.2
  - 0.1
  - 0.0
  - -0.1
  - -0.2
  - -0.3
regression analysis was applied to generate the risk score model. Collectively, six genes [monoamine oxidase A, CD36, fatty acid elongase 2, alcohol dehydrogenase 4, gamma-glutamyltransferase 5, ELOVL4] were included in the risk model (Figure 1D-E). The risk score for each patient was calculated based on the model and the patients were categorized into high- and low-risk groups (Figure 1F-G).

Correlation between risk model score and clinical features
We defined TCGA-GC cases as the training cohort and GEO cases as the validation cohort. In total, 339 patients with GC were recruited from TCGA database. Of these, 169 were considered to have high risk and 170 were considered to have low risk using the median risk score value. The relationship between clinical characteristics and risk model score was investigated, including age, sex, tumor grade, and T/M/N stages. No significant differences between groups were detected according to sex, M stage, and tumor grade (Figure 2A-C). Nonetheless, higher risk scores were associated with higher T (tumor invasion) and N (lymphoid metastasis) stages and with older age (Figure 2D-F). Furthermore, patients with higher risk scores had lower survival rates (Figure 2C), which was validated in the validation group based on patient data derived from the GEO database (GSE84437) (Figure 2H), including 231 patients classified as high-risk cohort and 202 patients classified as low-risk cohort. Moreover, time- and variable-dependent ROC analysis was performed to verify the results (Figure 2I-J). Univariable and multivariable regression models were constructed according to age, sex, tumor grade, tumor stage, and risk score. The risk score was an independent prognostic predictor of overall survival (Figure 2K-L).

Establishment of predictive nomogram in patients with GC
We constructed a nomogram involving tumor grade, T/N/M stages, sex, tumor stage, and risk score to predict overall survival in patients with GC (Figure 3A). The calibration curves at 1-, 3-, and 5 years demonstrated that the nomogram was relevant to overall survival in patients with GC (Figure 3B). Multivariable regression analysis revealed nomogram score as an independent index (Figure 3C), which may be a superior indicator than other clinical features used in clinical practice (Figure 3D).

A FAM-related model predicting response to chemotherapy and GSVA in high- and low-risk groups
The FAM-related risk score is associated with overall survival in patients with GC; therefore, demonstrating the association between risk score and chemotherapy response is important. The “pRophetic” R package was used to calculate the half maximal inhibitory concentration, which was applied to evaluate the sensitivity of the risk score and response to 5-Fluorouracil (5-FU). As shown in Figure 4A-B, the high-risk group was more sensitive to 5-FU in TCGA cohort. Furthermore, a negative relationship was noted between risk score and progression-free survival, indicating that the high-risk group may be more sensitive to chemotherapy (Figure 4C). However, its exclusive molecular type and tumor mutation burden facilitated the progression of tumor by activation of focal adhesion pathways, transformation of growth factor-beta signaling, and contraction of vascular smooth muscle (Figure 4D), ultimately shortening survival. These findings are consistent with previously reported results[12,13]. In line with previous studies, GSVA was performed to investigate the biological features between high- and low-risk groups by implementing “c2.cp.kegg.v7.2” in R Studio acquired from the Molecular Signature Database. As shown in Figure 4D, DNA replication, mismatch repair, and steroid biosynthesis were highly enriched in the low-risk group. Some molecules incorporating the transcription activator BRG1 (SMARCA4) and ataxia telangiectasia mutated (ATM) proteins are reportedly correlated with immune activation.
Figure 2 Prognostic correlation of fatty acid metabolism-related genes risk score model and clinical features as well as overall survival in gastric cancer patients. A-F: Correlation between risk score model and clinical characteristics comprising Age, Gender, Grade, M, N, T; G-H: Differences of overall survival between high- and low-risk cohorts from TCGA-cohort and GEO-cohort were detected; I: ROC curves were performed to identify the forecast value; J: Predictive correlation of the risk score as well as clinical features in TCGA-cohort; K-L: Univariate and multivariate cox regression models were proceeded to illustrate the prognostic value of the risk model.

Figure 3 verification of the risk model in gastric cancer patients. A. nomogram was plotted based on the Cancer Genome Atlas -cohort; B: Calibration of nomogram was calculated; C: Cox regression analysis of the nomogram; D: Receiver operating characteristic curves were drawn to identify the forecast value of nomogram.
Figure 4 Correlation of risk score and therapeutic strategies. A: Relationship between risk score and 5-fluorouracil sensitivity; B: Correlation of risk score and evaluated IC50 of 5-fluorouracil; C: Progression free survival between high- and low-risk cohorts; D: Gene set variation analysis enrichment analysis in high- and low-risk cohorts; E-F: Differences of immune activity related genes consisting of ataxia telangiectasia mutated and SMARCA4.
Figure 5 Activity of fatty acid metabolism related risk model in the context of tumor immune infiltration. A: Immune cell function in high- and low-risk cohorts; B: Immune cell infiltration in high- and low-risk cohorts; C: Relationship between risk score and immune subtypes using clustering analysis; D: Correlation between risk score and Tumor Immune Dysfunction and Exclusion.

Our results indicate that ATM mutation is associated with a positive response to immunotherapy.

**Immune differences between high- and low-risk groups**

Regarding immune cell infiltration, distinctive enrichment of macrophage M2 was detected in the high-risk group, in line with the previous survival analysis (Figure 5A). Additionally, para-inflammation, T cell co-inhibition, T cell co-stimulation, type I interferon (IFN) response, and type II IFN response were activated in the high-risk group (Figure 5B). Different immune subtypes were identified (Figure 5C) and validated using the TIDE (Tumor Immune Dysfunction and Exclusion) algorithm.

**Functional enrichment analysis of FAM-related DEGs in the low- and high-risk score groups based on PPI**

The expression profiles of DEGs were collected and analyzed to establish a PPI network using a STRING online database, which was then visualized using Cytoscape. As shown in Figure 6A, upregulated genes in the high-risk group are labeled in red, and those in the low-risk group are labeled in blue. Thereafter, the CytoHubba plug-in package was applied to generate the hub genes of FAM-related DEGs. In general, 10 genes (integrin beta (ITGB)-3, integrin alpha (ITGA)-1, fibronectin (FN)-1, fibroblast growth factor (FGF)-2, von Willebrand factor (VWF), ITGA5, ITGA4, ITGA8, thrombospondin (THBS)-1, ITGA9) were selected (Figure 6B). Functional enrichment analysis was performed using the “GOplot” R package, and these genes were involved in the integrin-mediated signaling pathway, cell-substrate adhesion, cell-matrix adhesion (Figure 6C), extracellular matrix-receptor, phosphoinositide 3-kinase-Akt signaling pathway, focal adhesion, and regulation of actin cytoskeleton (Figure 6D). Finally, survival and correlation analyses were conducted to determine the key regulators including FGF2 and THBS1, which were verified to be negatively associated with survival, consistent with previous studies (Figure 6E-F).
DISCUSSION

Cancer proliferation and progression are associated with metabolic reprogramming[14-17]. The metabolism alteration theory was first proposed by Otto Warburg in the 1920s and is known as the “Warburg phenomenon,” characterized by increased glycolysis in the context of an environment lacking oxygen[18,19]. Lactic acids generated from glycolysis favored tumor evasion and metastasis and restrained the antitumor immune effect[7,8,20]. In addition, glucose was converted into nicotinamide adenine dinucleotide phosphate by cancer cells to cope with the complex tumor environment thereby promoting fatty acid synthesis[21-23]. Meanwhile, the medium pyruvate generated from glycolysis was manipulated by the cancer cells to enter a truncated tricarboxylic acid cycle, thereby creating acetyl-CoA that was utilized for long-chain fatty acid synthesis. Collectively, this process highlights the involvement of FAM in cancer development and metastasis. Few studies have identified the role of FAM in GC. Cui et al concluded that abnormal FAM had discernible effects on GC growth[24,25]. Aberrant expression of FAM-related genes was associated with chemotherapeutic drug resistance and recurrence. Sterol O-acyltransferase (SOAT)1 was highly expressed in GC tissues and negatively related to GC prognosis via regulation of sterol regulatory element-binding protein (SREBP)-1 and SREBP2.
expression, which propelled lymph-angiogenesis through increased expression of vascular endothelial growth factor C [26]. However, other innovative mechanisms of FAM in GC warrant further investigation. In this study, we explored and elaborated on the relationship between FAM-related genes and GC using TCGA and GEO databases. FAM-related genes incorporated into the present study were obtained as previously described. We conducted a differential analysis to identify DEGs. A total of 113 FAM-related genes were screened to detect genes involved in GC progression, tumor microenvironment involvement, and prognosis. In total, 17 genes were included to establish a predictive/prognostic risk model using Cox regression and then verified using LASSO regression analysis. TCGA cohort was considered as the training set and the GEO cohort as the validation set. The overall survival prediction of the risk score (each sample from TCGA cohort had a risk score, which was used to classify patients into high-risk and low-risk cohorts) was constructed in TCGA database and verified in the GEO database. The risk score generated from this model was confirmed as an independent and accurate prognostic index.

Chemotherapeutic sensitivity between high-risk and low-risk groups was analyzed to evaluate the predictive value of the risk model in drugs screen in GC treatment. The increased risk score was positively associated with 5-FU resistance, consistent with previous studies [27]. In parallel, patients in the high-risk score group had reduced survival rates, suggesting that the risk model based on FAM-related genes may be applied to determine the optimal treatment (chemotherapy vs radiation therapy) for patients with GC. Moreover, patients from the high-risk score group were enriched in stroma immune activation, indicating cytotoxic drug resistance, consistent with previously reported studies [28-30]. Furthermore, high-risk score patients exhibited activation of the type I IFN response, T cell co-inhibition, type II IFN response, and para-inflammation function, demonstrating that patients with high-risk scores may benefit from immunotherapy, on account of the TIDE analysis. Altogether, the predictive/prognostic risk model established in this study may be valuable in clinical practice.

Significant differences in gene expression were detected between the high-risk and low-risk core cohorts. Therefore, we further evaluated FAM-related genes from the risk model. Expression of fatty acid binding protein 4 (FABP4), THBS1, and other marker levels were significantly different between the two cohorts. Various studies have suggested that pro- or antitumor manifestation of FABP4 was associated with various cancer types [31-33]. Further, FABP4 reportedly promotes breast cancer cell invasion by regulating the interleukin-6/signal transducer and activator of the transcription-3 axes. Moreover, its inhibition by BM-309403 (inhibitory molecule of FABP4) can prevent the proliferation and metastasis of ovarian cancer. Additionally, increased expression of FABP4 has been associated with a worse prognosis in GC, although Chen et al. [34] came to a contrary conclusion. On the contrary, increased FABP4 expression prohibited tumor progression and metastasis in hepatocellular carcinoma. Accordingly, THBS1 was identified as a hub gene that can serve as an indicator for GC diagnosis. However, its predictive and prognostic role in patients with GC remains elusive. Consequently, demonstrating the role of FABP4 and THBS1 in GC in future studies is important and requires urgent attention.

CONCLUSION
We constructed a fatty acid risk score model to assess the intact fatty acid features in GC. This risk model combined with clinicopathological characteristics, prognosis, chemotherapy sensitivity, and immune cell function, can be used to develop personalized treatment strategies for patients with GC. This study may sharpen and enrich the rationale used in prediction models to optimize the care of patients with GC.

ARTICLE HIGHLIGHTS

Research background
the interactions between solitary metabolic features and the surrounding complex tumor environment characterize cancer. fatty acids are the essential components of diverse types of lipids, which are crucial mediators in energy metabolism and signal transduction. Although various molecules have been identified in gastric cancer (GC) metastasis, uncovering novel links between fatty acids and the tumor environment is necessary to comprehensively understand gastric cancer.

Research motivation
we constructed a novel prognostic risk model for GC based on fatty acid metastasis (FAM) -related genes. We examined the mechanisms underlying FAM in GC, the relationship between the risk of GC and tumor microenvironment characteristics, and treatment strategies for GC.

Research objectives
we want to construct novel links between fatty acids and the tumor environment to contribute to accurate diagnosis, prognosis prediction, and recurrence risk and metastasis assessments in patients with GC.

Research methods
Data download and analysis; Detection of differentially expressed genes and functional enrichment analysis between
normal and cancer samples; Establishment and validation of prognostic risk model; Principal component analysis and

gene set variation analysis; Construction of protein-protein interaction network

**Research results**
Functional analysis of FAM-related genes between normal and cancer samples from TCGA database; Construction and
validation of the prognostic risk model in GC; Correlation between risk model score and clinical features; Establishment
of predictive nomogram in patients with GC; A FAM-related model predicting response to chemotherapy and GSVA in
high- and low-risk groups; Immune differences between high- and low-risk groups; Functional enrichment analysis of
FAM-related DEGs in the low- and high-risk score groups based on protein-protein interaction.

**Research conclusions**
A fatty acid risk score model to assess the intact fatty acid features in GC was constructed. This risk model combined with
clinicopathological characteristics, prognosis, chemotherapy sensitivity, and immune cell function.

**Research perspectives**
We established a prognostic risk model using data collected from The Cancer Genome Atlas database, explored the
function of the risk model, and identified the relationship between the risk model and clinical features.

**FOOTNOTES**

**Author contributions:** Fu Y was responsible for the data collection and manuscript preparation; Gao ZZ and Zhang L were responsible for data analysis and manuscript; Fu P was responsible for data analysis; Bao Y was responsible for manuscript preparation.

**Institutional review board statement:** All analyses were based on publicly available online datasets; thus, no ethical approval and patient consent were required.

**Informed consent statement:** All analyses were based on publicly available online datasets; thus, no informed consent statements were applied.

**Conflict-of-interest statement:** All the authors have no conflict of interest related to the manuscript.

**Data sharing statement:** The original anonymous dataset is available on request from the corresponding author at
sophiever0112@163.com.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: [https://creativecommons.org/Licenses/by-nc/4.0/](https://creativecommons.org/Licenses/by-nc/4.0/)

**Country/Territory of origin:** China

**ORCID number:** Yu Fu [0009-0006-4943-3052]; Bin Wang [0009-0001-3207-5985]; Peng Fu [0000-0003-2982-6300]; Lei Zhang [0009-0008-7141-4098]; Yi Bao [0009-0006-0038-689X]; Zhen-Zhen Gao [0000-0002-9518-7634].

**S-Editor:** Liu JH

**L-Editor:** A

**P-Editor:** Chen YX

**REFERENCES**


Metabolism and Immune Microenvironment. Biochem Biophys Res Commun 2022; 4813: 34-33

CD36 expression miR-23b and modulates TCF4 in gastric cancer. 33401771

Immunother Cancer N, Shi M, Kim KM, Liao W. Tumor microenvironment evaluation promotes precise checkpoint immunotherapy of advanced gastric cancer. 10.7150/ijbs.64714

Effectively prevent the progression of nonalcoholic steatohepatitis to liver cancer. DOI: 10.1016/j.celrep.2021.109190

Adenocarcinoma. WJCC, Chen D, Lu Q, Yao Y, Ji C. Bioinformatic Profiling Identifies a Fatty Acid Metabolism-Related Gene Risk Signature for Malignancy, Fu L, Jin L. Immunotherapy of gastric cancer: Past, future perspective and challenges. DOI: 10.1007/s11912-022-01223-1

et al, H. Fatty acid Metabolism in Ovarian Cancer: Therapeutic Implications. Int J Mol Sci 2022; 23: 35216285 DOI: 10.3390/ijms23042170


The New Era of Immunotherapy in Gastric Cancer. Cancers (Basel) 2022; 14: 35205802 DOI: 10.3390/cancers14041054

Metabolism and Cancer Immunotherapy. Curr Oncol Rep 2022; 24: 659-670 DOI: 35230593

Yoon H, Lee S. Fatty Acid Metabolism in Ovarian Cancer: Therapeutic Implications. Int J Mol Sci 2022; 23: 35216285 DOI: 10.3390/ijms23042170


Takei S, Kawazoe A, Shirata K. Fatty acid Metabolism in Gastric Cancer Immunotherapy. Cancers (Basel) 2022; 14: 35205802 DOI: 10.3390/cancers14041054

Ohshima K, Moriri E. Metabolic Reprogramming of Cancer Cells during Tumor Progression and Metastasis. Metabolites 2021; 11 (DOI: 33401771 DOI:10.3390/metabolites11010028)


Cui MY, Yi X, Zhu DX, Wu J. The Role of Lipid Metabolism in Gastric Cancer. Front Oncol 2022; 12: 916661 DOI: 35785165 DOI:10.3389/onco.2022.916661


Chen Y, Yuan H, Yu Q, Pang J, Sheng M, Tang W. Bioinformatics Analysis and Structure of Gastric Cancer Prognosis Model Based on Lipid Metabolism and Immune Microenvironment. Genes (Basel) 2022; 13 DOI: 36140749 DOI:10.3390/genes13091581